On July 24, Tempus AI fell 5.26% in regular trading, trading at $43.76/share, with turnover of $80.24 million.

On the news front, multiple headwinds converged to pressure the stock. The company is set to report Q2 earnings on July 30, with consensus expecting revenue of approximately $380 million, representing a deceleration from 36.12% year-over-year growth last quarter to 27.92%, while adjusted EPS is expected at -$0.14. Pre-earnings uncertainty suppressed risk appetite. Additionally, Tempus AI announced a $1.5 billion all-stock acquisition of Personalis at $16.25 per share earlier this week, aiming to integrate its NeXT Personal minimal residual disease detection platform into its AI-driven precision oncology system. While Needham affirmed the acquisition valuation as reasonable, market concerns over funding pressure and integration risks persisted.

The broader Life Sciences Tools and Services sector also traded lower, with Thermo Fisher Scientific down 2.43%, West Pharmaceutical down 4.08%, Waters down 2.57%, Danaher down 0.36%, and Medpace down 0.66%, amplifying sector-wide selling pressure on individual names.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)